CTIS2023-505845-17-00进行中(未招募)1 期
Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation and virologically controlled: a phase II, open-label, non-comparative pilot study. - Drive Off Road
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Adult patient living with HIV-1, Receiving stable antiretroviral treatment for at least 3 months, HIV RNA VL<50cp/mL for at least 6 months, Presence of the M184V/I mutation in at least one previous genotype performed on plasma HIV-RNA (at least 6 months undetectable), but absent from the genotype on current standard proviral DNA (Sanger technique), Signed informed consent
排除标准
- •M184V/I mutation present at inclusion on the standard proviral DNA genotype (Sanger technique), Renal failure with CrCl < 50ml/min, History of genotypic mutation associated with resistance to DOR or TDF, Contraindication to the use of DOR/TDF/3TC, Hypersensitivity to doravirine, tenofovir, lamivudine or one of the excipients (notably lactose), Current or recent treatments with a strong CYP3A4 inducer, Feeding with milk, Pregnancy, Patient already under DOR, Patients under guardianship or curatorship
研究者
相似试验
进行中(未招募)
Unknown
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsEffectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsInfections and InfestationsISRCTN80908109GlaxoSmithKline (China) Investment Co., Ltd.2,000
招募中
不适用
Efficacy and safety of tenofovir disoproxil fumarete (TDF) in nucleos(t)ide analogue-naive patients with hepatitis B virusPatients with chronic hepatitis B virus infectionJPRN-UMIN000017728Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology200
进行中(未招募)
1 期
The effect of two related HIV-medicines (TDF and TAF) on small intestine gut wall - could that explain why TDF seems to decrease and TAF to increase body weightHIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF)EUCTR2022-000849-32-FIHelsinki University Hospital24
尚未招募
不适用
Efficacy and Safety of Vireal®(Tenofovir Disoproxil Orotate) in Chronic Hepatitis B Patients Previously Treated with Viread®(Tenofovir Disoproxil Fumarate)KCT0004185Soon Chun Hyang University Hospital Seoul64
Unknown
不适用
Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral TherapyAIDS/HIV PROBLEMNCT01844297Peking Union Medical College500
